Clinical trial / 2022
Cocoa extract supplementation did not significantly reduce total cardiovascular events in older adults, but reduced cardiovascular death by 27%.
The COSMOS trial randomized 21,442 older US adults to a cocoa extract supplement (500 mg flavanols/d, including 80 mg epicatechin) or placebo for a median follow-up of 3.6 years. Cocoa extract did not significantly reduce confirmed total cardiovascular events (410 vs 456 participants; HR: 0.90; 95% CI: 0.78, 1.02; P = 0.11). However, secondary endpoints showed a significant reduction in cardiovascular death (HR: 0.73; 95% CI: 0.54, 0.98), while per-protocol analysis indicated a lower risk of total events (HR: 0.85; 95% CI: 0.72, 0.99). All-cause mortality (HR: 0.89; 95% CI: 0.77, 1.03) and other individual endpoints were not significantly different, and no safety concerns were observed.
- Study type
- Randomized, double-blind, placebo-controlled, 2-by-2 factorial trial
- Who was studied
- 21,442 US adults (12,666 women aged >=65 y and 8,776 men aged >=60 y) free of major CVD and recent cancer
- What was measured
- Composite of confirmed incident total cardiovascular events; secondary CVD endpoints and all-cause mortality
THE PAPER
Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial.
Sesso HD, Manson JE, Aragaki AK, Rist PM, Johnson LG, Friedenberg G, Copeland T, Clar A, Mora S, Moorthy MV, Sarkissian A, Carrick WR, Anderson GL, COSMOS Research Group. Am J Clin Nutr, 2022.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.